description
AldrichCPR
form
solid
SMILES string
O=C(N1)C(SC1=O)CC(C=C2)=CC=C2OCCC(N=C3)=CC=C3CC
InChI
1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)
InChI key
HYAFETHFCAUJAY-UHFFFAOYSA-N
Gene Information
human ... PPARG(5468)
Other Notes
请注意，Sigma-Aldrich 向早期发现研究人员提供该产品，作为独特化学品集合的一部分。Sigma-Aldrich 不收集本品的分析数据。买方负责确认产品标识和/或纯度。所有销售均为最终产品。
即使Sigma-Aldrich的标准销售条款和条件或Sigma-Aldrich与买方之间的协议中有任何相反的规定，SIGMA-ALDRICH仍“按原样”销售本产品，且不就本产品做出任何声明或保证，包括 (A) 适销性保证，(B) 特定用途的适合性保证，或 (C) 针对第三方知识产权侵权的保证，无论是否由法律、交易过程、履行过程、贸易使用或其他原因引起。
即使Sigma-Aldrich的标准销售条款和条件或Sigma-Aldrich与买方之间的协议中有任何相反的规定，SIGMA-ALDRICH仍“按原样”销售本产品，且不就本产品做出任何声明或保证，包括 (A) 适销性保证，(B) 特定用途的适合性保证，或 (C) 针对第三方知识产权侵权的保证，无论是否由法律、交易过程、履行过程、贸易使用或其他原因引起。
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Carc. 2
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Lawrence H Young et al.
Circulation, 135(20), 1882-1893 (2017-03-02)
Insulin resistance is highly prevalent among patients with atherosclerosis and is associated with an increased risk for myocardial infarction (MI) and stroke. The IRIS trial (Insulin Resistance Intervention after Stroke) demonstrated that pioglitazone decreased the composite risk for fatal or
Lourdes Ibáñez et al.
The Journal of adolescent health : official publication of the Society for Adolescent Medicine, 61(4), 446-453 (2017-07-18)
Polycystic ovary syndrome (PCOS) is an increasingly prevalent disorder in adolescent girls, commonly presenting with hirsutism/oligomenorrhea, commonly treated with an oral contraceptive (OC), and commonly followed by oligoanovulatory subfertility. We tested whether an intervention targeting the reduction of hepato-visceral adiposity
Mukul R Jain et al.
Liver international : official journal of the International Association for the Study of the Liver, 38(6), 1084-1094 (2017-11-23)
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are common clinico-pathological conditions that affect millions of patients worldwide. In this study, the efficacy of saroglitazar, a novel PPARα/γ agonist, was assessed in models of NAFLD/NASH. HepG2 cells treated with
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| CDS021593-50MG | 04061828994007 |